HOME
pISSN 2005-9159
eISSN 2093-0569

Best Practice

Table of Contents

1. Website

  • The URL address of the official journal web site is http://epain.org.
  • Aims & Scope statement: The mission of the Korean Journal of Pain (KJP) is to improve the care of patients in pain by providing a forum for basic scientists, clinical researchers, clinicians, and other health professionals. The KJP aims to offer state-of-the-art practical information on the basic mechanisms, prevention, and management of pain. Specific topics covered by the KJP include, but are not limited to, basic and applied pain research, interventional procedures, neuromodulation, palliative care, multi-disciplinary treatments, patient education, and health policy. Its regional focus is mainly Korea, but it also welcomes submissions from researchers all over the world.
  • Readership: The KJP is primarily for pain physicians who seek updated information about pain medicine, but its readership can be also include those in other positions; basic scientists can read about recent research topics and detailed research methods; clinicians can have access to updated information concerning the topic of pain medicine; medical teachers are able to familiarize themselves with a variety of medical education data; students can understand recent trends of pain medicine; allied health professionals, including nurses and physical therapists, can have access to recent information on the care of patients with pain; and policy makers can reflect on the results of the research to apply to nation-wide policies for patients with pain. The public, especially those who suffer from pain, are also able to get information on advancements in their treatment, increasing their knowledge, and inspiring confidence in the clinicians’ and researchers’ devotion
  • Authorship criteria: According to the ICMJE guidelines, the authors of the KJP must have met all of the following criteria: 1) substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of data; 2) drafting the article or reviewing it critically for important intellectual content; 3) final approval of the version to be published; 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. After the initial submission of a manuscript, any changes whatsoever in authorship must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. After publication of the paper, no further changes are permitted.
  • Duplicate submission and redundant publication: All submitted manuscript should be original and should not be considered by other scientific journals for publication at the same time. Upon receipt, submitted manuscripts are screened for possible plagiarism or duplicate publication using Crossref Similarity Check. If plagiarism or duplicate submission is detected, the submitted manuscript will be rejected, the offenders may be penalized, and the institutions affiliated with the authors will be notified. A letter of permission is required for any and all materials that have been published previously.
  • pISSN: 2005-9159; eISSN 2093-0569

2. Name of journal

The official journal title is the Korean Journal of Pain. The abbreviated title is Korean J Pain.

3. Peer review process

Every manuscript is reviewed by the editorial office to ensure that the submission includes all the required components. Submissions lacking the necessary parts, as outlined in the instructions for authors, will not be accepted. Once confirmed, manuscripts are forwarded to the section editor. If the manuscript is deemed meritorious and appropriate for the journal, the section editor assigns the manuscript to an editor. The assigned editor oversees the manuscript’s review process, involving two or more external experts in the relevant field or the members of the editorial board. The journal employs a double-blind peer review process: the reviewers and authors remain anonymous to each other. The editor, considering the reviewers’ feedback and their own assessment of the manuscript, drafts a decision letter, which is then submitted to the journal office. This decision letter is subsequently communicated to the author via email. If the concerns of the reviewers and an editor are not adequately addressed by the revision process, the editorial board will decide whether to continue the review process. The final decision on manuscript approval for publication is made by the section editor. The section editor may request any further corrections, revisions, and deletions to the article text as necessary. Statistical editing may also be conducted if professional statistical review is required, which is performed by a statistical editor or statistician. Editors never handle their own manuscript, even if they are commissioned to write them. The KJP does not guarantee acceptance without review or short peer review times. Commissioned manuscripts are also subject to review before publication.

4. Ownership and management

  • Information about the ownership: This journal is owned by the publisher, the Korean Pain Society (http://painfree.or.kr).
  • Management team of the journal: https://www.epain.org/about/editorial.php
    Journal management team (2022-2024)
    • - Journal manager: Francis S. Nahm (Seoul National University, Korea)
    • - Manager of the review process: Seong Ae Yoo (Korean Pain Society)
    • - Ethics editor:
        Eun Soo Kim (Pusan National University, Korea)
        Ho-Jin Lee (Seoul National University, Korea)
        Young Hoon Jeon (Kyungpook National University, Korea)
        Jeong Gill Leem (University of Ulsan, Korea)
        Kyung Hoon Kim (Pusan National University, Korea)
        Hue Jeong Park (Catholic University, Korea)
        Hwa Yong Shin (Choong-Ang University, Korea)
    • - Statistical editor:
        Hyeseon Lee (Pohang University of Science and Technology)
        Sang Gyu Kwak (Daegu Catholic University, Korea)
    • - Manuscript editor: Hai Mi Koo (MEDrang Inc., Korea)
    • - Website and JATS XML file producers: Eun Seok Chae (Inforang, Inc., Korea)

5. Advisory body

The advisory body is the journal’s editorial board. The names and affiliations of all editorial board members are listed on the journal’s homepage under the Editorial Board tab (https://www.epain.org/about/editorial.php)

6. Editorial team/contact information

  • Editorial team: https://www.epain.org/about/editorial.php
  • Contact information
    Editorial office of The Korean Pain Society.
    #1705, 240 Gangnam-daero, Gangnam-gu, Seoul 06267, Korea
    Tel: +82-2-6241-7582, Fax: +82-2-6241-8275,
    E-mail: editorial_office@painfree.or.kr

7. Copyright and licensing

  • Copyright policy: Copyrights of all published materials are owned by the Korean Pain Society. Every authors must complete and submit the journal’s copyright transfer agreement. Permission must be obtained from the Korean Pain Society for any commercial use of materials.
  • Licensing information: Articles in the Korean Journal of Pain are distributed under the terms of the Creative Commons Attribution License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited (https://creativecommons.org/licenses/by-nc/4.0/).
  • Deposit policy: According to the deposit policy (selfarchiving policy) of Sherpa/Romeo (http://www.sherpa.ac.uk), authors cannot archive pre-print (i.e., pre-refereeing), but they can archive post-print (i.e., final draft post-refereeing). Authors can archive the publisher’s version/PDF.

8. Author fees

There is no submission fee or article processing charge. Also, color printing is free. The whole cost occurred during the publication process is provided by the Korean Pain Society, barring any change of policy.

9. Process for identification of and dealing with allegations of research misconduct

The editorial office screens all submitted manuscripts for plagiarism, using a sophisticated software program, prior to peer review. When the journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, or other issues, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The Editorial Board of the KJP will discuss the suspected cases and reach a decision. The KJP will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.

10. Publication ethics and related editorial policies

  • Journal policies on authorship and contributorship: The authors of the KJP must have met all of the following criteria: 1) substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of data; 2) drafting the article or reviewing it critically for important intellectual content; 3) final approval of the version to be published; 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. After the initial submission of a manuscript, any changes whatsoever in authorship must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. After publication of the paper, no further changes is permitted.
  • How the journal will handle complaints and appeals: The policy of the journal is primarily aimed at protecting the authors, reviewers, editors, and publisher of the journal. Authors, reviewers, and readers may register complaints and appeals in a variety of cases as follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias, or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal issues. If any individuals or institutions want to provide information about such cases, they can send a letter to the editor. For complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, and why) should be provided. The process of handling complaints and appeals follows the COPE guidelines (https://publicationethics.org/appeals)
  • Journal policies on conflicts of interest/competing interests: The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data. Examples of potential conflicts of interest are financial relationships such as employment, consultancies, stock ownership, honoraria, and paid expert testimony. Conflicts can occur for other reasons as well, such as personal relationships, academic competition, and intellectual passion. In particular, all sources of funding applicable to the study should be explicitly stated. If there are any conflicts of interest, authors should disclose them in the manuscript.
  • Journal policies on data sharing and reproducibility: The KJP accepts the ICMJE recommendations for data sharing policy (http://icmje.org/icmje-recommendations.pdf). All manuscripts reporting clinical trial results should submit a data sharing statement following the ICMJE guidelines. If the data is already public, its URL site or sources should be disclosed. If the data cannot be publicized, the issue can be negotiated with the editor.
  • The journal’s policy on ethical oversight: When the journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, or an ethical problem, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The editorial board will discuss the suspected cases and reach a decision. The KJP will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when misconduct is found.
  • The journal’s policy on intellectual property: All published papers become the permanent property of the Korean Pain Society (http://painfree.or.kr). Copyrights of all published materials are owned by the Korean Pain Society.
  • The journal’s options for post-publication discussion and corrections: Post-publication discussion is available through letters to the editor. If any readers have a concern on any articles published, they can submit a letter to the editor about the article. If any errors or mistakes in the article are found, they can be corrected through errata, corrigenda, or retraction.

11. Publishing schedule

The Koran Journal of Pain is published four times a year on the first business day of January, April, July, and October.

12. Access

The Korean Journal of Pain is an open access journal of which articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. (https://creativecommons.org/licenses/by-nc/4.0/").

13. Archiving

The full text of the Korean Journal of Pain can be accessible without barrier from PubMed Central (https://pubmedcentral.gov), the Korea Citation Index (http://kci.go.kr), and the National Library of Korea (http://nl.go.kr) in the event that the journal is no longer published.

14. Other revenue

Revenue sources of the journal include the support of its publisher (the Korean Pain Society), the Korean Federation of Science and Technology Societies, and advertising rates.

15. Advertising policy

KJP accepts advertisements on the following basis:
  • Eligibility of the advertised products or services
    • - All products or services should be safe and reliable, and not cause any harm to the health and welfare of humans. Advertisements may promote information and technologies relevant for authors, editors, reviewers, and readers. Pharmaceutical products may also be considered.
    • - Advertising is separate from content. Advertisers and sponsors have no advance knowledge of our editorial contents, nor do the editors have advance knowledge of advertisers. Content is never altered, added, or deleted to accommodate advertising. Advertisers and sponsors have no input regarding any of our editorial decisions or advertising policies.
    • - We reserve the right to decline or cancel any advertisement at any time.
    • - Advertisements for pharmaceutical products must conform to all regulations and policies of the Ministry of Food and Drug Safety, Republic of Korea, in every respect.
  • Orders
    Any individuals or organizations who are interested in advertising their products or services in the print copies of the journal or on its website are encouraged to contact the editorial office. The acceptance of advertisement will be discussed by the editorial board and will be ultimately approved by the publisher.
  • Advertisement fee
    For one print copy issue, the advertisement price for one whole page is KRW 700,000 (USD 700).
  • Disclaimer
    • - Liability: Neither the publisher nor the editors will be legally liable for advertisements presented in the journal. In addition, they cannot guarantee the accuracy, completeness, or usefulness of the information provided.
    • - Endorsement: The publisher and the editors do not endorse any products or services that are advertised.
    • - Disclaimer: Neither the publisher nor the authors will be legally liable for any of the content of advertisements, so readers must keep this in mind when reading or seeing advertisements.

16. Direct marketing

Journal propagation has been done through the journal website and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.

e-submission

Vol. 38, Issue 1

Editor-in-Chief: Francis S. Nahm, MD, PhD
eISSN: 2093-0569
pISSN: 2005-9159
Frequency: Quarterly
2023 JCR Impact Factor 3.4